Clinical significance of determination of surrogate markers of angiogenesis in breast cancer

Dvorak, 1986, Tumors: wounds that not heal. Similarities between tumor stroma generation and wound healing, New Engl. J. Med., 315, 1650 Hynes, 1992, Integrins: versatility, modulation, and signaling in cell adhesion, Cell, 69, 11, 10.1016/0092-8674(92)90115-S Cunha, 1994, Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate, Cancer, 74, 1030, 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q Weiss, 1988, Interactions of cancer cells with the microvasculature during metastasis, FASEB J., 2, 12, 10.1096/fasebj.2.1.3275560 Liotta, 1986, Tumor invasion and metastases-role of the extracellular matrix. Rhoads Memorial Award Lecture, Cancer Res., 46, 1 Bernstein, 1994, Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis, Curr. Opin. Oncol., 6, 106, 10.1097/00001622-199401000-00015 Koch, 1995, Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1, Nature, 376, 517, 10.1038/376517a0 Strömblad, 1996, Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvß3 during angiogenesis, J. Clin. Invest., 98, 426, 10.1172/JCI118808 Giancotti, 1999, Integrin signaling, Science, 285, 1028, 10.1126/science.285.5430.1028 Huang, 1999, The structural and mechanical complexity of cell-growth control, Nat. Cell Biol., 1, 131, 10.1038/13043 Leibovich, 1987, Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α, Nature, 329, 630, 10.1038/329630a0 Ware, 1993, Platelet-endothelium interactions, New Engl. J. Med., 328, 628, 10.1056/NEJM199303043280907 Camps, 1990, Fibroblast-mediated acceleration of human epithelial tumor growth in vivo, Proc. Natl. Acad. Sci. USA, 87, 75, 10.1073/pnas.87.1.75 Poole, 1983, Stimulation of rat peritoneal mast cell migration by tumor-derived peptides, Cancer Res., 43, 5857 Zhang, 1995, The isolation and long-term culture of normal human endometrial epithelium and stroma, J. Cell Sci., 108, 323, 10.1242/jcs.108.1.323 Asahara, 1997, Isolation of putative progenitor endothelial cells for angiogenesis, Science, 275, 964, 10.1126/science.275.5302.964 Harrison, 1997, Cellular and molecular mechanisms of endothelial cell dysfunction, J. Clin. Invest., 100, 2153, 10.1172/JCI119751 Hunt, 1998, Endothelial cell activation, Br. Med. J., 316, 1328, 10.1136/bmj.316.7141.1328 Hirashima, 1999, Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis, Blood, 93, 1253, 10.1182/blood.V93.4.1253 Folkman, 1989, What is the evidence that tumors are angiogenesis dependent?, J. Natl. Cancer Inst., 82, 4, 10.1093/jnci/82.1.4 Folkman, 1995, Clinical applications of research on angiogenesis, New Engl. J. Med., 333, 1757, 10.1056/NEJM199512283332608 Hanahan, 1996, Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7 Folkman, 1995, Angiogenesis in cancer, vascular, rheumatoid and other disease, Nat. Med., 1, 27, 10.1038/nm0195-27 Brooks, 1994, Requirement of vascular αvβ3 for angiogenesis, Science, 264, 569, 10.1126/science.7512751 Ferrara, 1999, Clinical application of angiogenic growth factors and their inhibitors, Nat. Med., 5, 1359, 10.1038/70928 Folkman, 1995, Angiogenesis inhibitors generated by tumors, Mol. Med., 1, 120, 10.1007/BF03401559 Holmgren, 1996, Antiangiogensis restricted tumor dormancy, Cancer Met. Rev., 15, 241, 10.1007/BF00437478 Rak, 2000, Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-trasformed epithelial cells and fibroblasts, Cancer Res., 60, 490 Kerbel, 1996, Commentaries on tumor angiogenesis: an introduction, Cancer Met. Rev., 15, 145, 10.1007/BF00437465 Rak, 1995, Oncogenes as inducers of tumor angiogenesis, Cancer Met. Rev., 14, 263, 10.1007/BF00690598 Rak, 1995, Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis, Cancer Res., 55, 4575 Rosen, 1997, Regulation of angiogenesis by scatter factor, EXS, 79, 193 Sheibani, 1996, Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3, Cancer Lett., 107, 45, 10.1016/0304-3835(96)04341-8 Mettouchi, 1994, SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts, EMBO J., 13, 5668, 10.1002/j.1460-2075.1994.tb06905.x Brooks, 1996, Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3, Cell, 85, 683, 10.1016/S0092-8674(00)81235-0 Gomis-Rüth, 1997, Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1, Nature, 389, 77, 10.1038/37995 Wei, 1996, Regulation of integrin function by the urokinase receptor, Science, 273, 1551, 10.1126/science.273.5281.1551 Bischoff, 1997, Cell adhesion and angiogenesis, J. Clin. Invest., 99, 373, 10.1172/JCI119168 Shatti, 1997, Integrin signaling in vascular biology, J. Clin. Invest., 100, 1, 10.1172/JCI119500 Gasparini, 1997, p53 and angiogenesis in neoplasia, 115 Dameron, 1994, Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1, Science, 265, 1582, 10.1126/science.7521539 Volpert, 1995, The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression, Breast Cancer Res. Treat., 36, 119, 10.1007/BF00666034 Kaelin, 1998, Functions of the von Hippel-Lindau tumour suppressor protein, J. Intern. Med, 243, 535, 10.1046/j.1365-2796.1998.00335.x Kondo, 1994, bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells, Exp. Cell Res., 213, 428, 10.1006/excr.1994.1219 Wojnowski, 1997, Endothelial apoptosis in braf-deficient mice, Nat. Genet., 16, 293, 10.1038/ng0797-293 Katoh, 1995, Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation, Cancer Res., 55, 5687 Pollman, 1998, Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease, Nat. Med., 4, 222, 10.1038/nm0298-222 Holmgren, 1995, Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nat. Med., 1, 149, 10.1038/nm0295-149 Claesson-Welsh, 1998, Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD, Proc. Natl. Acad. Sci. USA, 95, 5579, 10.1073/pnas.95.10.5579 Guo, 1997, Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells, Cancer Res., 57, 1735 Hisano, 1999, Induction and suppression of endothelial cell apoptosis by sphingolipids: a possible in vitro model for cell-cell interactions between platelets and endothelial cell, Blood, 93, 4293, 10.1182/blood.V93.12.4293 Fidler, 1994, The implications of angiogenesis for the biology and therapy of cancer metastasis, Cell, 79, 185, 10.1016/0092-8674(94)90187-2 Hori, 1991, Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor, Cancer Res., 51, 6180 Kim, 1993, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, 362, 841, 10.1038/362841a0 O'Reilly, 1997, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277, 10.1016/S0092-8674(00)81848-6 Gasparini, 1999, The rationale and future potential of angiogenesis inhibitors in neoplasia, Drugs, 58, 17, 10.2165/00003495-199958010-00003 Weidner, 1991, Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma, New Engl. J. Med., 324, 1, 10.1056/NEJM199101033240101 Vermeulen, 1996, Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation, Eur. J. Cancer, 32, 2474, 10.1016/S0959-8049(96)00379-6 Horak, 1992, Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer, Lancet, 340, 1120, 10.1016/0140-6736(92)93150-L Weidner, 1994, Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients, Breast Cancer Res. Treat., 29, 97, 10.1007/BF00666185 Bosari, 1992, Microvessel quantification and prognosis in invasive breast carcinoma, Hum. Pathol., 23, 755, 10.1016/0046-8177(92)90344-3 Van Hoef, 1993, Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer, Eur. J. Cancer, 29A, 1141 Khanuja, 1993, Angiogenesis quantitation as a prognostic factor for primary breast carcinoma 2 cms or less, 226 Obermair, 1994, Influence of tumoral microvessel density on the recurrence-free survival in human breast cancer: preliminary results, Onkologie, 17, 44, 10.1159/000218380 Ogawa, 1995, Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen, Br. J. Cancer, 71, 1297, 10.1038/bjc.1995.251 Hall, 1992, Is the relationship between angiogenesis and metastasis in breast cancer real?, Surg. Oncol., 1, 223, 10.1016/0960-7404(92)90068-V Costello, 1995, Prognostic significance of microvessel density in lymph node negative breast carcinoma, Hum. Pathol., 26, 1181, 10.1016/0046-8177(95)90190-6 Toi, 1995, Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression, Breast Cancer Res. Treat., 36, 193, 10.1007/BF00666040 Obermair, 1995, Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival, Int. J. Cancer, 62, 126, 10.1002/ijc.2910620203 Axelsson, 1995, Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma, J. Natl. Cancer Inst., 87, 997, 10.1093/jnci/87.13.997 De Placido, 1999, Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up, Clin. Cancer Res., 5, 2854 Kohlberger PD, Obermair A, Sliutz G, et al. Quantitative immunohistochemistry of factor VIII-related antigen in breast carcinoma, Am. J. Clin Pathol 1996; 705–10. Narita, 1998, Independent prognostic factors in breast cancer patients, Am. J. Surg., 175, 73, 10.1016/S0002-9610(97)00225-0 Aceñero, 1998, Vascular enumeration as a significant prognosticator for invasive breast carcinoma, J. Clin. Oncol., 16, 1684, 10.1200/JCO.1998.16.5.1684 Morphopoulos, 1996, Tumour angiogenesis as a prognostic marker in infiltrating loubular carcinoma of the breast, J. Pathol., 180, 44, 10.1002/(SICI)1096-9896(199609)180:1<44::AID-PATH648>3.0.CO;2-C Lee, 1997, Lymph node negative invasive breast carcinoma 1 centrimeter or less in size (T1a,bNOMO). Clinicopathologic features and outcome, Cancer, 79, 761, 10.1002/(SICI)1097-0142(19970215)79:4<761::AID-CNCR13>3.0.CO;2-Y Kato, 1999, The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long-term survival in japanese patients with breast cancer, Breast Cancer Res. Treat., 53, 19, 10.1023/A:1006193024382 Toi, 1993, Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma, Int. J. Cancer, 55, 371, 10.1002/ijc.2910550305 Sterns, 1997, Macromolecular interstitital clearance, tumour vascularity, other prognostic factors and breast cancer survival, Breast Cancer Res. Treat., 42, 113, 10.1023/A:1005749825449 Medri, 2000, Tumor microvessel density and prognosis in node-negative breast cancer, Int. J. Cancer (Pred. Oncol.), 89, 74, 10.1002/(SICI)1097-0215(20000120)89:1<74::AID-IJC12>3.0.CO;2-L Fox, 1995, Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis, J. Pathol., 177, 275, 10.1002/path.1711770310 Gasparini, 1995, Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy, Cancer J. Sci. Am., 1, 131 Macaulay, 1995, Breast cancer angiogenesis and tamoxifen resistance, End-Rel Cancer, 2, 97, 10.1677/erc.0.0020097 Bevilacqua, 1995, Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma. Results of a multiparametric study, Breast Cancer Res. Treat., 36, 205, 10.1007/BF00666041 Gasparini, 1996, Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients, Clin. Cancer Res., 2, 1191 Siitonen, 1995, Comparison of different immunohistochemical methods in the assessment of angiogenesis: Lack of prognostic value in a group of 77 selected node-negative breast carcinomas, Modern Pathol., 8, 745 Toi, 1993, Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma, Int. J. Cancer, 55, 371, 10.1002/ijc.2910550305 Fox, 1994, Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival, Breast Cancer Res. Treat., 29, 109, 10.1007/BF00666186 Barbareschi, 1995, Microvessel density quantification in breast carcinomas, Appl. Immunohistochem., 3, 75 Jacquemier, 1998, Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis, J. Pathol., 184, 130, 10.1002/(SICI)1096-9896(199802)184:2<130::AID-PATH19>3.0.CO;2-W Viens, 1999, Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjiuvant chemotherapy, Breast Cancer Res. Treat., 54, 205, 10.1023/A:1006112927565 Chu, 1998, The prognostic significance of tumor angiogenesis in Tawiwanese patients with invasive ductal breast carcinomas, Cancer Lett., 134, 7, 10.1016/S0304-3835(98)00231-6 Gasparini, 1994, Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma, J. Clin. Oncol., 12, 454, 10.1200/JCO.1994.12.3.454 Leek, 1996, Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma, Cancer Res., 56, 4625 Goulding, 1995, Assessment of angiogenesis in breast carcinoma: an important factor in prognosis?, Hum. Pathol., 26, 1196, 10.1016/0046-8177(95)90193-0 Gerson, 1999, Angiogenesis in breast cancer, Proc. Am. Soc. Clin. Oncol., 18, 2433 Hansen, 2000, The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients, Clin. Cancer Res., 6, 139 Heimann, 1996, Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer, J. Natl. Cancer Inst., 88, 1764, 10.1093/jnci/88.23.1764 Simpson, 1996, Endothelial area as a prognostic indicator for invasive breast carcinoma, Cancer, 77, 2077, 10.1002/(SICI)1097-0142(19960515)77:10<2077::AID-CNCR17>3.0.CO;2-S Visscher, 1993, Prognostic significance of image morphometric microvessel enumeration in breast carcinoma, Analyte Quant. Cytol. Histol., 15, 88 Gasparini, 1998, Vascular integrin αvβ3: A new prognostic indicator in breast cancer, Clin. Cancer Res., 4, 2625 Kumar, 1999, Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis, Cancer Res., 59, 856 Heimann, 2000, Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin, Cancer Res., 60, 298 Brooks, 1995, Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin, J. Clin. Invest., 96, 1815, 10.1172/JCI118227 Nicosia, 1998, What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?, Am. J. Pathol., 153, 11, 10.1016/S0002-9440(10)65539-3 Fukumara, 1998, Tumor induction of VEGF promoter activity in stromal cells, Cell, 94, 715, 10.1016/S0092-8674(00)81731-6 Dvorak, 1995, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, Am. J. Pathol., 146, 1029 Ferrara, 1992, Molecular and biological properties of the vascular endothelial growth factor family of proteins, Endocrine Rev., 13, 18, 10.1210/edrv-13-1-18 Shalaby, 1997, A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis, Cell, 89, 981, 10.1016/S0092-8674(00)80283-4 Gerber, 1999, VEGF is required for growth and survival in neonatal mice, Development, 126, 1149, 10.1242/dev.126.6.1149 Carmeliet, 1996, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature, 380, 435, 10.1038/380435a0 Grunstein, 1999, Tumor-derived expression of vascular endothelial growth factor is a critical factor expansion and vascular function, Cancer Res., 59, 1592 Brekken, 1998, Vascular endothelial growth factor as a marker of tumor endothelium, Cancer Res., 58, 1952 Senger, 1993, Vascular permeability factor (VPF, VEGF) in tumor biology, Breast Cancer Res. Treat., 12, 303 Senger, 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 219, 983, 10.1126/science.6823562 Yuan, 1996, Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody, Proc. Natl. Acad. Sci. USA, 93, 14765, 10.1073/pnas.93.25.14765 Kieser, 1994, Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression, Oncogene, 9, 963 He, 1999, Alternative spicing of vascular endothelial crowth factor (vegf)–r1 (flt-1) pre-mRNA is important for the regulation of vegf activity, Mol. Endocr., 13, 537, 10.1210/me.13.4.537 Tsurumi, 1997, Reciprocal relation between VEGF and NO in the regulation of endothelial integrity, Nat. Med., 3, 878, 10.1038/nm0897-879 Hornig, 1999, Soluble VEGF receptors, Angiogenesis, 3, 33, 10.1023/A:1009033017809 Moghaddam, 1995, Thymidine phphorylase is angiogenic and promotes tumor growth, Proc. Natl. Acad. Sci. USA, 92, 998, 10.1073/pnas.92.4.998 Haraguchi, 1994, Angiogenic activity of enzymes, Nature, 368, 198, 10.1038/368198a0 Folkman, 1996, What is the role of thymidine phosphorylase in tumor angiogenesis?, J. Natl. Cancer Inst., 88, 1091, 10.1093/jnci/88.16.1091 Fukuiwa, 1999, Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics, Cancer, 85, 960, 10.1002/(SICI)1097-0142(19990215)85:4<960::AID-CNCR26>3.0.CO;2-P Metzger, 1998, High basal level gene expression of thymidine phosphorymase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil, Clin. Cancer Res., 4, 2371 Griffiths, 1997, Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy, Br. J. Cancer, 6, 689, 10.1038/bjc.1997.447 Mason, 1994, The ins and outs of fibroblast growth factors, Cell, 78, 547, 10.1016/0092-8674(94)90520-7 Kern, 1996, The role of angiogenic growth factors in breast cancer progression, Cancer Met. Rev., 15, 213, 10.1007/BF00437474 Nabel, 1993, Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo, Nature, 362, 844, 10.1038/362844a0 Jouanneau, 1995, FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation, Growth Factor, 12, 37, 10.3109/08977199509003212 Coltrini, 1995, Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-I-B-cells: an export-dependent mechanism of action, Cancer Res., 55, 4729 Mohammadi, 1997, Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors, Science, 276, 955, 10.1126/science.276.5314.955 Plotnikov, 1999, Structural basis for FGF receptor dimerization and activation, Cell, 98, 641, 10.1016/S0092-8674(00)80051-3 Coope, 1997, The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue, Br. J. Cancer, 75, 1621, 10.1038/bjc.1997.277 Toi, 1994, Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer, Jpn. J. Cancer Res., 85, 1045, 10.1111/j.1349-7006.1994.tb02904.x Toi, 1996, Quantitative analysis of vascular endothelial growth factor in primary breast cancer, Cancer, 77, 1101, 10.1002/(SICI)1097-0142(19960315)77:6<1101::AID-CNCR15>3.0.CO;2-5 Gasparini, 1997, Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma, J. Natl. Cancer Inst., 89, 139, 10.1093/jnci/89.2.139 Toi, 1997, Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications, Angiogenesis, 1, 71, 10.1023/A:1018305132489 Gasparini, 1999, Clinical relevance of vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in patients with node-positive breast cancer treated either with adjuvant chemotherapy or hormonetherapy, Cancer J. Sci. Am., 5, 101 Toi, 1995, Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression, Breast Cancer Res. Treat., 36, 193, 10.1007/BF00666040 Obermair, 1997, Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival, Int. J. Cancer, 74, 455, 10.1002/(SICI)1097-0215(19970822)74:4<455::AID-IJC17>3.0.CO;2-8 Relf, 1997, Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factors, tumor growth factor β-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis, Cancer Res., 57, 963 Eppenberger, 1998, Markers of tumor angiogenesis and proteolysis independent define high- and low-risk subsets of node-negative cancer patients, J. Clin. Oncol., 16, 3129, 10.1200/JCO.1998.16.9.3129 Linderholm, 1998, Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma, J. Clin. Oncol., 16, 3121, 10.1200/JCO.1998.16.9.3121 Linderholm, 2000, p53 and vascular endothelial growth factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma, Int. J. Cancer, 89, 51, 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.0.CO;2-8 Linderholm, 1999, Does vascular endothelial growht factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?, Br. J. Cancer, 81, 727, 10.1038/sj.bjc.6690755 Corradini D, Pellizzaro C, Malimpietri D, et al. Vascular endothelial growth factor: a further prognostic factor in node-negative breast cancer? Tumori, Suppl. 1, 5, 1999. XXVI Symposium of the Italian Cancer Society, Milan, 22–24, November, 1999. Fox, 1996, The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium, Br. J. Cancer, 73, 275, 10.1038/bjc.1996.49 Fox, 1997, Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF, Ann. Oncol., 8, 271, 10.1023/A:1008280110558 Seymour, 1994, Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer, Breast Cancer Res. Treat., 32, 229, 10.1007/BF00665774 Engels, 1997, Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast, J. Pathol., 181, 207, 10.1002/(SICI)1096-9896(199702)181:2<207::AID-PATH758>3.0.CO;2-4 Nagaoka, 1998, Platelet-derived endothelial cell growth factor/hymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer, Int. J. Oncol., 13, 449 Colomer, 1997, Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma, Br. J. Cancer, 76, 1215, 10.1038/bjc.1997.536 Smith, 1999, Upregulation of basic fibroblast growth factor in breast cancinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival, Ann. Oncol., 10, 707, 10.1023/A:1008303614441 Laterra, 1997, Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo, Lab. Invest., 76, 565 Bussolino, 1992, Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell mobility and growth, J. Cell Biol., 119, 629, 10.1083/jcb.119.3.629 Yamashita, 1994, Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer, Cancer Res., 54, 1630 Nagy, 1996, Hepatocyte growth factor/scatter factor, angiogenesis and tumour cell proliferation in primary breast cancer, Breast, 5, 105, 10.1016/S0960-9776(96)90131-9 Taniguchi, 1995, Serum concentrations of hepatocyte growth factor in breast cancer patients, Clin. Cancer Res., 1, 1031 Nguyen, 1994, Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers, J. Natl. Cancer Inst., 86, 356, 10.1093/jnci/86.5.356 Nguyen, 1994, Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of bladder cancer patients, J. Natl. Cancer Inst., 85, 241, 10.1093/jnci/85.3.241 Yamamoto, 1996, Concentrations of vascular endothelial growth factor in sera of normal controls and cancer patients, Clin. Cancer Res., 2, 821 Banks, 1998, Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology, Br. J. Cancer, 77, 956, 10.1038/bjc.1998.158 Webb, 1998, Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease, Clin. Sci., 94, 395, 10.1042/cs0940395 Gunsilius, 2000, Thrombocytes are the major source for soluble vascular endothelial growth factor in peropheral blood, Oncology, 58, 169, 10.1159/000012095 Wynendaele, 1999, Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?, Ann. Oncol., 10, 965, 10.1023/A:1008377921886 Salven, 1999, Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor, Clin. Cancer Res., 5, 487 Gion G, Gasparini G. Il laboratorio oncologico: il cuore della ‘traslational research’ In: Amadori D (Ed.), L'organizzazione e la gestione delle Unità Operative di Oncologia. Centro Scientifico Editore, Torino, in press. Vermeulen, 1999, Blood platelets and serum VEGF in cancer patients, Br. J. Cancer, 79, 370, 10.1038/sj.bjc.6690059 Dirix, 1997, Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients, Br. J. Cancer, 76, 238, 10.1038/bjc.1997.368 Sliuts, 1995, Serum evaluation of basic FGF in breast cancer patients, Anticancer Res., 15, 2675 Toi, 1998, Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer, Clin. Cancer Res., 4, 659 Vermeulen, 1997, Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b, J. Natl. Cancer Inst., 89, 1316, 10.1093/jnci/89.17.1316 Gasparini, 1997, Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications?, Crit. Rev. Oncol. Hematol., 26, 147, 10.1016/S1040-8428(97)10001-4 Toi, 1999, Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma, Int. J. Oncol, 15, 1169 Gasparini G, Toi M, Biganzoli E. et al. Thrombospondins 1-2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology, in press. Bertin, 1997, Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia, Cancer Res., 57, 396 Fanelli, 1999, Assessment of tumor vascularization: immunohistochimical and non invasive methods, Int. J. Biol. Markers, 14, 218, 10.1177/172460089901400405 Van Zijl, 1998, Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging, Nat. Med., 4, 159, 10.1038/nm0298-159 Sipkins, 1998, Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging, Nat. Med., 4, 623, 10.1038/nm0598-623 Libutti, 1999, Monitoring responses to antiangiogenic agents using noninvasive imaging tests, Cancer J. Sci. Am., 5, 252 Kedar, 1995, Automated quantification of color Doppler signals: a preliminary study in breast tumors, Radiology, 197, 39, 10.1148/radiology.197.1.7568851 Veikkola, 2000, Regulation of angiogenesis via vascular endothelial growth factor receptors, Cancer Res., 60, 203 Gasparini G, Gion M. Molecular-targeted anticancer therapy: challanges related to study-design and choice of proper end-points. Cancer J (Boston, MA) 2000;6:117–131.